Marshall Wace’s Biohaven BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.69M Buy
651,349
+298,744
+85% +$3.22M 0.01% 1053
2026
Q1
$2.98M Buy
352,605
+322,578
+1,074% +$3.53M ﹤0.01% 1569
2025
Q4
$339K Buy
+30,027
New +$372K ﹤0.01% 2404
2025
Q3
Sell
-26,379
Closed -$372K 2900
2025
Q2
$372K Sell
26,379
-207,668
-89% -$3.7M ﹤0.01% 2248
2025
Q1
$5.63M Sell
234,047
-132,844
-36% -$4.68M 0.01% 1006
2024
Q4
$13.7M Sell
366,891
-4,778
-1% -$223K 0.02% 682
2024
Q3
$18.6M Buy
371,669
+266,101
+252% +$10.4M 0.02% 530
2024
Q2
$3.66M Sell
105,568
-677,724
-87% -$26.8M ﹤0.01% 1127
2024
Q1
$42.8M Buy
783,292
+394,775
+102% +$19.5M 0.07% 292
2023
Q4
$16.6M Sell
388,517
-842,299
-68% -$26.2M 0.03% 529
2023
Q3
$32M Buy
1,230,816
+144,803
+13% +$3.01M 0.06% 303
2023
Q2
$26M Sell
1,086,013
-518,235
-32% -$8.92M 0.05% 387
2023
Q1
$21.9M Sell
1,604,248
-553,519
-26% -$8.81M 0.05% 438
2022
Q4
$29.9M Buy
2,157,767
+840,808
+64% +$11.9M 0.07% 330
2022
Q3
$8.11M Buy
+1,316,959
New +$9.56M 0.02% 1045

Other funds holding BHVN

Marshall Wace's BHVN Position: Q2 2026 in Review

Marshall Wace increased its Biohaven (BHVN) stake by 85% in Q2 2026, buying an estimated $3.22M and bringing the position to 651,349 shares worth $9.69M. The position accounts for 0.01% of the portfolio, ranked #1053.

Marshall Wace first reported a position in BHVN in Q3 2022 and has held it in 15 quarters since. The position peaked at $42.8M in Q1 2024. 296 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

  • Marshall Wace held 651,349 shares of Biohaven worth $9.69M as of Q2 2026.
  • Marshall Wace bought 298,744 Biohaven shares in Q2 2026, an estimated $3.22M.
  • Biohaven made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1053 holding.
  • Marshall Wace first reported a position in Biohaven in Q3 2022 and has held it in 15 quarters since.
  • Marshall Wace's Biohaven position peaked at $42.8M in Q1 2024.
  • 296 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.